UT-Southwestern Medical Center: Combined Therapy Makes Headway for Liver Cancer
May 03, 2024
May 03, 2024
DALLAS, Texas, May 3 (TNSres) -- The University of Texas Southwestern Medical Center issued the following news release:
A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two clinical trial conducted by UT Southwestern Medical Center. The findings, published in Nature Communications, show the potential benefits of aug . . .
A drug that targets a protein known as phosphatidylserine boosted the response rate for hepatocellular carcinoma (HCC) patients receiving immunotherapy without compromising their safety, according to results of a phase two clinical trial conducted by UT Southwestern Medical Center. The findings, published in Nature Communications, show the potential benefits of aug . . .